Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2017

View Archived Issues

NewLink Genetics synthesizes indoximod prodrug for cancer immunotherapy

Pan-TRK inhibitor CH-7057288 active against TRK fusion-driven cancer in vivo

Discovery and clinical data detailed for IDO-1 inhibitor BMS-986205

DS-5141 designated under Japanese Sakigake designation system

Phase Ib/II topline results for Resolaris in early-onset facioscapulohumeral muscular dystrophy

Preliminary results from the SIGNAL trial of VX-15 in Huntington's disease

Cara reports encouraging data from phase I safety trial of intravenous CR-845

Kissei discontinues development of KCT-0809 for dry eye associated with Sjogren's syndrome

BD set to acquire Bard

CMV pp65-LAMP vaccination results in survival benefit in patients with glioblastoma

Akari presents new data on Coversin

Clinigen and Onxeo agree to launch managed access program for Beleodaq in Europe

Xoma reports phase II results for X-213 in prolactin inhibition

EMA committee recommends approval of Skilarence for psoriasis

Auris Medical reports results from Keyzilen extension study AMPACT2 in acute inner ear tinnitus

MONARCH 3 trial of abemaciclib in breast cancer meets primary endpoint

Aducanumab designated under Japanese Sakigake designation system for Alzheimer's disease

Japanese Sakigake designation awarded to Opdivo for biliary tract cancer

Subgroups benefit from lefitolimod in phase II IMPULSE trial in small-cell lung cancer

Denovo gains exclusive worldwide license to liafensine

CSPC Zhongqi Pharmaceutical Technology identifies MAPK14 inhibitors

Rhythm Pharmaceuticals patents melanocortin MC4 receptor agonists

Novartis and Amgen expand commercialization agreement for AMG-334

Five drugs assigned target products under Japanese Sakigake designation system

Cetirizine evaluated as add-on treatment for neuromyelitis optica

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...